Abacus Wealth Partners’s Guardant Health GH Stock Holding History

Abacus Wealth Partners’s Portfolio GH Stock Details GH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-2,273	Closed	-$232K	–	526
2025 Q4	$232K	Buy	+2,273	New	+$203K	0.02%	431

Other funds holding GH

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Abacus Wealth Partners's GH Position: Q1 2026 in Review

Abacus Wealth Partners sold out of Guardant Health (GH) in Q1 2026, closing a stake of 2,273 shares — an estimated $232K sold.

Abacus Wealth Partners first reported a position in GH in Q4 2025 and held it in 1 quarter. The position peaked at $232K in Q4 2025. 486 funds tracked by Wall St. Rank hold GH as of Q1 2026.

Abacus Wealth Partners reported no remaining Guardant Health position as of Q1 2026 after selling out during the quarter.
Abacus Wealth Partners sold 2,273 Guardant Health shares in Q1 2026, an estimated $232K.
Abacus Wealth Partners first reported a position in Guardant Health in Q4 2025 and held it in 1 quarter.
Abacus Wealth Partners's Guardant Health position peaked at $232K in Q4 2025.
486 funds tracked by Wall St. Rank held Guardant Health as of Q1 2026.

Based on Abacus Wealth Partners's 13F filing for Q1 2026, filed 24 Apr 2026.